Genetic determination of acute phase reactant levels: The strong heart study

Human Heredity

Volumn 58, Issue 2, 2004, Pages 112-116

  Best, Lyle G ^a,h   North, Kari E ^b   Tracy, Russell P ^c   Lee, Elisa T ^d   Howard, Barbara V ^e   Palmieri, Vittorio ^f   MacCluer, Jean W ^g  

^a MISSOURI BREAKS INDUSTRIES RESEARCH INC   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e MEDSTAR RESEARCH INSTITUTE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^h Missouri Breaks Industries Research Inc   (United States)

Author keywords

C reactive protein; Cardiovascular diseases; Epidemiology; Fibrinogen; Genetics; Inflammation; Plasminogen activator inhibitor 1; Risk factors

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENETICS; HEREDITY; HUMAN; INDIA; MALE; PHENOTYPE; QUANTITATIVE GENETICS; RACE; WESTERN HEMISPHERE; ANALYSIS OF VARIANCE; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; HEART MUSCLE; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

AGED; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FIBRINOGEN; HUMANS; LIKELIHOOD FUNCTIONS; MIDDLE AGED; MODELS, BIOLOGICAL; MYOCARDIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 18444412897     PISSN: 00015652     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083032     Document Type: Article

References (28)

1. Ridker PM: Novel risk factors and markers for coronary disease. Adv Intern Med 2000;45:391-418.
2. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
3. Kohler HP, Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801.
4. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP: Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001;154:681-689.
5. Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, Lathrop M, Ratcliffe PJ, Watkins HC, Keavney B: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002;53:1029-1034.
6. Pankow JS, Folsom AR, Province MA, Rao DC, Williams RR, Eckfeldt J, Sellers TA: Segregation analysis of plasminogen activator inhibitor-1 and fibrinogen levels in the NHLBI family heart study. Arterioscler Thromb Vasc Biol 1998;18:1559-1567.
7. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I: Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol 1998;18:84-91.
8. Freeman MS, Mansfield MW, Barrett JH, Grant PJ: Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol 2002;22:506-510.
9. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996;94:2057-2063.
10. Ford ES, Giles WH: Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: Findings from National Health and Nutrition Examination Survey III. J Clin Epidemiol 2000;53:95-102.
11. Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, Cucchiara AJ, Savage PJ, Howard BV: The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132:1141-1155.
12. Macy EM, Hayes TE, Tracy RP: Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-58.
13. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D: Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71:220-225.
14. Geffken DF, Keating FG, Kennedy MH, Cornell ES, Bovill EG, Tracy RP: The measurement of fibrinogen in population-based research. Studies on instrumentation and methodology. Arch Pathol Lab Med 1994;118:1106-1109.
15. Almasy L, Blangero J: Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998;62:1198-1211.
16. Howard BV, Lee ET, Cowan LD, Devereux RB, Galloway JM, Go OT, Howard WJ, Rhoades ER, Robbins DC, Sievers ML, Welty TK: Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 1999;99:2389-2395.
17. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM: C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: Are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001;21:603-610.
18. North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabsitz RR, Roman MJ, MacCluer JW: Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am J Epidemiol 2003;157:303-314.
19. Becker TM, Wiggins C, Peek C, Key CR, Samet JM: Mortality from infectious diseases among New Mexico's American Indians, Hispanic whites, and other whites, 1958-87. Am J Public Health 1990;80:320-323.
20. Howard BV, Welty TK, Fabsitz RR, Cowan LD, Oopik AJ, Le NA, Yeh J, Savage PJ, Lee ET: Risk factors for coronary heart disease in diabetic and nondiabetic Native Americans: The Strong Heart Study. Diabetes 1992;41 (suppl 2):4-11.
21. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP: Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-722.
22. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA: Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002;161:233-242.
23. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL: Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003;88:255-259.
24. Ando R, Doi M, Yamauchi K, Chida Y, Ida T, Endo K, Yanagi H, Tomura S: Association of beta-fibrinogen and factor VII polymorphism with plasma fibrinogen and factor VII levels, and no association of PAI-1 polymorphism with plasma PAI-1 levels in hemodialysis patients. Clin Nephrol 2002;58:25-32.
25. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP: Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002;3:14-19.
26. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Antonio Tataranni P, Bogardus C, Hanson RL: A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 2003;78:136-144.
27. de Maat MP, Bladbjerg EM, Johansen LG, de Knijff P, Gram J, Kluft C, Jespersen J: DNA-polymorphisms and plasma levels of vascular disease risk factors in Greenland Inuit - is there a relation with the low risk of cardiovascular disease in the Inuit? Thromb Haemost 1999;81:547-552.
28. Festa A, D'Agostino R Jr, Rich SS, Jenny NS, Tracy RP, Haffner SM: Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003;107:2422-2427.